The study was performed on 25 patients diagnosed with liver tumors, assigned magnetic resonance imaging (MRI) with Primovist - a hepatospecific paramagnetic gadolinium-based contrast agent at the International Medical Center of Hue Central Hospital. The result is as followed: 11 HCCs, 1 biliary tract malignant tumor, 1 hepatic adenoma, 6 metastates, 2 FNH, 1 hepatic AML, 3 hemangiomas. 47 lesions in total, including 9 lesions smaller than 1cm, 12 lesions 1-2 cm, 26 lesions larger than 2 cm. All 11 HCCs are hypointense on T1W, hyperintense on T2W, intratumoral high signal on DWI, 9 cases have typical enhancement pattern on Dynamic phase (arterial enhancement with washout assessed on the portal venous phase), 10 cases have no enhancement on Hepatocellular phase. Metastasis lesions have peripheral enhancement on both arterial and venous phases, no enhancement on delayed phase due to not having hepatic cells. The the biliary tract tumor is pathologically correct, with minor peripheral enhancement 30 seconds after injection, gradual centripetal enhancement after 60 and 90 seconds, no enhancement on delayed phase due to not having hepatic cells. 3 cases with hemangiomas are hyperintense on T2WI, similar to blood vessels, hypointense on T1WI, pheripherally enhanced 30 seconds after injection, fully centripetal fill-in after 90 seconds, non-enhanced on delayed phase (20 minutes) due to not having hepatic cells. 2 cases with FNH have iso- or mildly hyperintense on T1W, isointense on T2W and hypointense on DWI, isointense on hepatocellular phase due to the reservation of hepatic cells. Liver MRI with Primovist is specific for Hepatic cells, playing a critical role in detecting small lesions and differentiating benign and malignant lesions of the liver, especially those without typical enhancement pattern on Dynamic phase.